Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Equities researchers at Jefferies Group issued their Q1 2018 earnings estimates for shares of Bellicum Pharmaceuticals in a research report issued on Tuesday, March 13th, Zacks Investment Research reports. Jefferies Group analyst B. Amin forecasts that the biopharmaceutical company will post earnings of ($0.71) per share for the quarter. Jefferies Group also issued estimates for Bellicum Pharmaceuticals’ Q2 2018 earnings at ($0.75) EPS, Q3 2018 earnings at ($0.79) EPS and Q4 2018 earnings at ($0.69) EPS.
Other research analysts have also recently issued research reports about the stock. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. SunTrust Banks dropped their price target on Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research note on Wednesday, January 31st. Zacks Investment Research raised Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Wednesday, January 10th. Cantor Fitzgerald set a $10.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Citigroup raised their price target on Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $16.88.
Shares of Bellicum Pharmaceuticals stock traded down $0.27 on Thursday, hitting $6.39. The stock had a trading volume of 312,031 shares, compared to its average volume of 561,094. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.37 and a current ratio of 8.37. Bellicum Pharmaceuticals has a one year low of $5.02 and a one year high of $14.49. The stock has a market capitalization of $214.53, a price-to-earnings ratio of -2.25 and a beta of 0.47.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.08. The firm had revenue of ($0.07) million during the quarter, compared to the consensus estimate of $0.08 million.
A number of institutional investors have recently made changes to their positions in BLCM. MYDA Advisors LLC purchased a new position in Bellicum Pharmaceuticals during the fourth quarter valued at $118,000. Voya Investment Management LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at $132,000. LPL Financial LLC purchased a new position in Bellicum Pharmaceuticals during the fourth quarter valued at $140,000. Commonwealth Equity Services Inc purchased a new position in Bellicum Pharmaceuticals during the third quarter valued at $142,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Bellicum Pharmaceuticals during the third quarter valued at $164,000. 54.57% of the stock is owned by institutional investors and hedge funds.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the firm’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total transaction of $2,248,978.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 1,141,822 shares of company stock valued at $9,475,583 in the last three months. Insiders own 18.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/jefferies-group-comments-on-bellicum-pharmaceuticals-incs-q1-2018-earnings-blcm.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.